Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098390 | 0.94 | PIK3CD (0.50) | CYP1A2TDP1PIK3CDKDM1AHTR7 | |
| SCHEMBL378022 | 0.87 | CYP1A2 (0.56) | CYP1A2TDP1PIK3CDKDM1AHTR7 | |
| SCHEMBL23823660 | 0.84 | CYP1A2 (0.64) | CYP1A2TDP1PIK3CDKDM1AHTR7 | |
| SCHEMBL297316 | 0.83 | CYP1A2 (0.52) | CYP1A2TDP1PIK3CDKDM1AHTR7 | |
| SCHEMBL24694352 | 0.83 | CYP1A2 (0.52) | CYP1A2TDP1PIK3CDKDM1AHTR7 | |
| SCHEMBL4910227 | 0.83 | CYP1A2 (0.52) | CYP1A2TDP1PIK3CDKDM1AHTR7 | |
| SCHEMBL27370872 | 0.82 | HTR7 (0.49) | CYP1A2TDP1PIK3CDKDM1AHTR7 | |
| SCHEMBL12744551 | 0.82 | PAOX (0.61) | CYP1A2TDP1PIK3CDKDM1AHTR7 | |
| SCHEMBL8265175 | 0.82 | CYP1A2 (0.50) | CYP1A2TDP1PIK3CDKDM1AHTR7 | |
| SCHEMBL4360278 | 0.82 | PIK3CD (0.50) | CYP1A2TDP1PIK3CDKDM1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | claimed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | claimed |
| EP-3498716-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | Hongyun Biotech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| US-7772432-B2 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | claimed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | claimed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | claimed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1163212-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | claimed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | claimed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000055120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | CYP1A2 583/4885TDP1 2226/4885PIK3CD 2313/4885 |
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | CYP1A2 642/4885TDP1 2121/4885PIK3CD 2629/4885 |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | CYP1A2 1209/4885TDP1 1408/4885PIK3CD 96/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | CYP1A2 1209/4885TDP1 1408/4885PIK3CD 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.